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Abstract
Background: Although Drug resistance tuberculosis is not a new phenomenon, Mali remains one of the “blank”
countries without systematic data.
Methods: Between 2006 and 2014, we enrolled pulmonary TB patients from local TB diagnostics centers and a
university referral hospital in several observational cohort studies. These consecutive patients had first line drug
susceptibility testing (DST) performed on their isolates. A subset of MDR was subsequently tested for second line
drug resistance.
Results: A total of 1186 mycobacterial cultures were performed on samples from 522 patients, including 1105
sputa and 81 blood samples, yielding one or more Mycobacterium tuberculosis complex (Mtbc) positive cultures for
343 patients. Phenotypic DST was performed on 337 (98.3%) unique Mtbc isolates, of which 127 (37.7%) were
resistant to at least one drug, including 75 (22.3%) with multidrug resistance (MDR). The overall prevalence of MDR-
TB was 3.4% among new patients and 66.3% among retreatment patients. Second line DST was available for 38 (50.
7%) of MDR patients and seven (18.4%) had resistance to either fluoroquinolones or second-line injectable drugs.
Conclusion: The drug resistance levels, including MDR, found in this study are relatively high, likely related to the
selected referral population. While worrisome, the numbers remained stable over the study period. These findings
prompt a nationwide drug resistance survey, as well as continuous surveillance of all retreatment patients, which
will provide more accurate results on countrywide drug resistance rates and ensure that MDR patients access
appropriate second line treatment.
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Background
Tuberculosis (TB) continues to be a global public health
concern with an estimated 9.6 million incident cases, and
1.5 million deaths worldwide in 2014 [1]. The global esti-
mate in 2014 of multidrug-resistant TB (MDR-TB) was
480 000 new patients worldwide including cases of pri-
mary and acquired MDR-TB [1], of whom 190, 000 died
[1]. Drug resistant tuberculosis (DR-TB) continues to
threaten global tuberculosis control, resulting from either
primary infection with resistant bacteria or from acquired
resistance. MDR-TB is results from bacteria that are resist-
ant to at least isoniazid and rifampicin, the most effective
anti-TB drugs available. Extensively drug-resistant TB
(XDR-TB) strains are additionally resistant to any fluoro-
quinolone and any of the second-line anti-TB injectable
drugs (amikacin, kanamycin or capreomycin).
Mali, a large country with limited resources, reported in
2014 9800 new TB patients, including 40 MDR-TB pa-
tients [1]. The world health organization (WHO) esti-
mates the number of MDR cases in Mali to be 130 among
notified pulmonary TB patients, based on sub-national
data assumptions, as no formal drug resistance survey has
been conducted to date [1]. In Mali, individual patient
drug susceptibility testing (DST) is not universally access-
ible, with only few laboratories capable of performing such
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activity: the national TB reference laboratory (NRL) and
the biosafety level 3 (BSL-3) laboratory of SEREFO (HIV
and TB research and training center of the University of
Sciences, Techniques and Technologies of Bamako
(USTTB) conduct phenotypic testing, while the private
Charles Mérieux Institute laboratory has implemented the
Hain MTBDRplus Line Probe Assay to detect resistance
mutations to isoniazid and rifampicin. Thus, DST is re-
stricted at the NRL to retreatment patients, such as those
who fail, lost to follow up, or relapse after completion of
the standardized 6 months first line therapy and no sys-
tematic testing for drug resistance in new TB patients has
been performed to date in Mali.
However, at SEREFO, DST has been conducted since
2006 for each new and retreatment patient enrolled in
research protocols. In addition, per national guidelines,
all suspected DR-TB patients are referred to the NRL for
culture and DST, and MDR patients are referred to the
TB unit of the university teaching hospital of Point-G,
Bamako, for further assessment and second line therapy.
Thus, MDR patients included in SEREFO’s protocols
have had parallel culture and DST conducted as external
quality control (QC) for the NRL, essentially monitoring
consecutive retreatment patients in Mali since 2006.
Although DR-TB is not a new phenomenon, Mali re-
mains one of the ‘blank’ countries without systematic
data in the WHO reports, in contrast to other countries
in the region, such as Benin and Senegal [2, 3]. In the
absence of a nationwide drug resistance survey, we
present the evolution of tuberculosis drug resistance
among new and retreatment patients, and reviewed the
demographic features of patients, drugs resistance pro-
files and disease characteristics of MDR-TB in Mali over
the 9 year period from 2006 to 2014.
Methods
Study design and setting
Between 2006 and 2014, we conducted multiple descriptive
cohort studies by enrolling pulmonary TB patients from
local reference centers and the University Teaching Hos-
pital at Point G, in Bamako, Mali, whose mycobacterial iso-
lates had been cryopreserved. In the present cross-sectional
analysis, we pooled baseline drug susceptibility testing by
treatment history for all patients who enrolled in any of the
studies, and referred a subset of cryopreserved isolates to
MRC Gambia for additional phenotypic resistance testing.
Mali is a landlocked West African country with a size of
1,241,248 km2 and population of approximately 14.5 mil-
lion people [4]. Bamako, the capital city, has a population
of approximately two million people and is divided into
six urban districts, with each district having a health refer-
ral center, where TB diagnostic and treatment services are
available. The university teaching hospital at point-g is lo-
cated in district three and serves as the main tuberculosis
reference center. In 2014 alone, more than one third of
the total TB patients in Mali were managed in Bamako,
and our study population, which represented more than
80% of the notified Malian retreatment cases, were all re-
ferred to point-g hospital for further investigations and ap-
propriate treatment [5].
Study population
Suspected pulmonary TB patients were screened at the
study sites based on smear positive result of either Ziehl
Neelsen (ZN) or Auramine/Rhodamine (A/R) staining
and consenting participants were enrolled into the stud-
ies (for in- and exclusion criteria see Additional file 1:
Table S1). Only TB patients who had Mycobacterium tu-
berculosis complex (Mtbc) disease confirmed by culture
were included in the final analysis (Additional file 1:
Table S1).
Patients were classified based on their TB treatment
history as new patients, who had received TB treatment
for less than 4 weeks, and as relapse and/or treatment
failure patients, who had received TB treatment for
more than 1 month according to protocol inclusion cri-
teria. However, in 2009 and 2010, there were few studies
running, and most patients screened at that period origi-
nated from the programmatic surveillance of retreat-
ment patients who were more likely to be drug resistant
patients. Patients were treated in accordance with na-
tional guidelines of the TB program in Mali [6]. New pa-
tients received a fixed dose combination of 2 months of
rifampicin (R), isoniazid (H), pyrazinamide (Z) and eth-
ambutol (E) and 4 months of (R) and (H) (2RHZE/4RH;
Cat 1), while re-treatment patients received 2 months of
(R), (H), (Z), (E) and streptomycin (S), followed by 1
month with the same combination but without (S) and 5
months of (R), (H), and (E) (2RHZES/1RHZE/5RHE;
Cat. 2). Patients clinically suspected of having MDR dis-
ease (those who failed Cat. 2 regimen) or confirmed
MDR-TB patients underwent a 6 month course of kana-
mycin (K), ofloxacin (O), ethionamide (Et) and (Z) dur-
ing the 6 months inpatients period, and followed by
15 months of the same combination without kanamycin
(6KOEtZ/15OEtZ) [6]. Per national guidelines, patients
with confirmed MDR were checked on a monthly basis
for treatment response by physical examination and
sample collection for microscopy and culture. During
the study period, programmatic treatment outcome was
monitored for confirmed MDR patients several months
after leaving the hospital while still on treatment, as well
as several months after treatment.
Laboratory tests
Pre-enrollment sputum smear microscopy by ZN or direct
fluorescent smear microscopy using Auramine/Rhodamine
(FM) at local reference centers was followed by indirect FM
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and culture at SEREFO laboratory, which is certified by the
college of American pathologists (CAP) as external quality
control. Confirmed Mtbc isolates underwent drug suscepti-
bility testing (DST). In the context of a regional collabor-
ation, subcultures had DST repeated for first line drugs,
plus second line DST for a randomly selected MDR isolates,
at the Medical Research Council (MRC) Unit, The Gambia.
Culture and susceptibility testing
Sputum specimens were digested and decontaminated
using the standard N-Acetyl-L-Cysteine/4% NaOH solu-
tion, concentrated by centrifugation (4500 rpm) and inoc-
ulated on both liquid (Mycobacterium Growth Incubator
Tube (BBL™ MGIT™ Becton Dickinson, Sparks MD,
USA)), and solid (Middlebrook 7H11 Agar and Selective
7H11 Agar) media. Simultaneously, an aliquot of concen-
trated specimen was prepared for indirect commercial
Auramine-Rhodamine staining (BBL™ Becton Dickinson,
Sparks MD, USA). Speciation of positive mycobacterial
cultures was based on acid fast bacilli (AFB) positivity in
fluorescent microscopy (FM) and colony morphology on
solid medium, and was confirmed by nucleic acid probes
(AccuProbe® GenProbe, San Diego, CA, USA). Indirect
drug susceptibility testing was performed on Mtbc isolates
using MGIT AST/SIRE System (Becton Dickinson,
Sparks, MD, USA) and the results were interpreted based
on the United States of America (USA) Center for Disease
Control (CDC) recommendations for critical drug con-
centrations [7]. Moreover, indirect DST by MGIT using
second line drugs, ofloxacin (OFX, 2 μg/mL), kanamycin
(KAN, 6.0 μg/mL), capreomycin (CAP, 2 · 5 μg/mL,
Sigma-Aldrich, St. Louis, Mo), USA was performed on
randomly selected MDR isolates at MRC, The Gambia. A
subset of MDR isolates identified from the repeated first
line drug susceptibility testing at the MRC underwent sec-
ond line drug susceptibility testing.
HIV testing
The human immunodeficiency virus (HIV) serology
status was determined using the following algorithm:
first, rapid testing was done with Determine® (HIV-1/
2, Abbott Laboratories, Matsudo-Shi, Chiba, Japan) for
all participants, followed by an ELISA test for all pa-
tients (Genscreen Ag-Ac UltraHIV-1/2 version 2
Assay, Bio-Rad Laboratories, Marnes, France), and any
positive ELISA test was confirmed by Western Blot
test (New Lav Blot I/II (New Lav Blot I and II, Bio-
Rad Laboratories, Marnes, France).
Data & statistical analysis
Univariate and multivariate analyses were conducted
with demographic and clinical variables to identify pre-
dictors of rifampicin resistance and MDR-TB. Results
were considered significant when p-values were less than
0.05. Analyses were performed using SAS version 9.1
(SAS Institute, Cary, NC) and Epi info version 3.5.3
(CDC, Atlanta, USA).
Results
A total of 1186 mycobacterial cultures were performed
in the SEREFO BSL-3 laboratory during the 9 year
period, on samples from 522 patients, including 1105
sputa and 81 blood samples. Of these patients, 343
(65.7%) grew Mtbc, 43 (8.2%) grew non-tuberculous
mycobacteria (NTM), 120 (23%) had a negative culture,
and 16 (3.1%) were contaminated (Fig. 1). Among the
522 patients, 395 (75.7%) were male and 69 (13.2%)
were HIV positive. Of the 343 patients in whom tuber-
culosis was culture confirmed, 242 (70.6%) were new
patients, and 101 (29.4%) were previously treated pa-
tients. The majority (61.8%) of the patients had been
enrolled in studies including both new and retreatment
patients, and the remainder in studies only including
new TB patients (Additional file 1: Table S1). Pheno-
typic drug susceptibility testing (DST) was performed
on 337 (98.3%) of the Mtbc isolates (Tables 1 and 2).
Prevalence of first-line drug resistance in our study
population
Among the 337 patients whose isolates underwent
DST, 127 (37.7%) had resistance to at least one drug,
including 75 (22.3%) multidrug resistant (MDR) cases.
We observed two (0.6%) rifampicin mono-resistant
isolates, and 12 (3.6%) isoniazid mono-resistant iso-
lates (Table 1). The prevalence of MDR-TB was 3.4%
among new patients and 66.7% among retreatment
patients (Table 2). Of the 75 MDR-TB patients, eight
(10.7%) were identified among new, and 67 (89.3%)
were identified among retreatment (Fig. 2, a and b).
Indirect FM was positive in 176 (84.6%) of patients
without resistance, and in 97 (78.9%) of the patients
with resistance (Table not shown). The prevalence of
polyresistance (defined as resistance to more than one
drug, except for MDR) was 4.2% among new TB pa-
tients, and 10.9% among previously treated patients
(Table 2). Retesting of first line DST results on 208
randomly selected isolates at MRC showed 99% con-
cordance for isoniazid, 98% for rifampicin, 92% for
ethambutol, and 91% for streptomycin (Table not
shown).
Demographic characteristics did not differ significantly
between patients with and without rifampicin resistance,
except for a higher proportion of patients with rifampi-
cin resistance with lower smear grades (AFB smear
negative and/or 1+/2+, compared with 3+, p < 0.01),
and, as expected, a higher rate of MDR-TB among previ-
ously treated patients (p = <0.01) (Table 3).
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Prevalence of second-line drug resistance
Second line antimycobacterial susceptibility testing at
MRC Unit, The Gambia including ofloxacin, kanamycin,
and capreomycin, was available for 38 (50.7%) of the
MDR-TB patients. While no XDR-TB was identified, the
prevalence of resistance to either a fluoroquinolone or
second-line injectable drug, but not both was 18.4%
(Table 4). The proportion of single second-line drug
resistance was 1/38 for ofloxacin, 1/38 for kanamycin,
and 5/38 for capreomycin (Table 4).
Outcome of MDR-TB patients
Programmatic outcome measurements were available for
45 (60%) of the MDR-TB patients, of whom 13 (30%) died,
15 (33%) were lost to follow up, and only 17 (37%) experi-
enced treatment success (treatment completion/cure).
Fig. 1 Flow chart of patients included in the study. Mtbc. = Mycobacterium tuberculosis complex, NTM=Non-tuberculous Mycobacteria, DST = Phenotypic
drug susceptibility Testing
Table 1 General profile of phenotypic drug susceptibility testing profile per year
Phenotypic drug susceptibility testing profile 2006 2007 2008 2009 2010 2011 2012 2013 2014 Total
Total number of isolates tested 18 53 33 15 10 29 53 87 39 337
Pan susceptible 18 37 22 2 1 16 34 63 17 210
S 0 1 3 0 0 0 2 8 2 16
I 0 0 1 1 0 2 4 2 2 12
R 0 1 0 0 0 0 0 0 1 2
E 0 0 0 0 0 0 1 0 0 1
S, I 0 1 2 2 0 0 1 5 5 16
S, I, E 0 1 0 0 0 0 1 1 0 3
S, R 0 0 0 0 0 0 0 0 1 1
S, R, E 0 0 0 0 0 0 0 0 1 1
S, I, R 0 2 0 0 2 0 0 0 1 5
I, R, E 0 2 1 1 0 1 0 0 0 5
I, R 0 1 1 0 0 3 1 0 4 10
S, I, R, E 0 7 3 9 7 7 9 8 5 55
Total # of MDR-TB per Year 0 12 5 10 9 11 10 8 10 75
% of MDR-TB per Year 0.00 22.6 15.2 66.7 90.0 37.9 18.9 9.2 25.6 22.3
S streptomycin, I isoniazid, R rifampicin, E ethambutol, MDR-TB multidrug resistance (resistance to at least isoniazid and rifampicin)
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Discussion
In resource limited settings with a high incidence of
tuberculosis, such as Mali, estimates of drug resist-
ance are incomplete. We present, here a report on
TB drug resistance profiles in Mali, over a 9 year
period, based on baseline DST results from new and
retreatment patients enrolled at the TB clinic of the
university teaching hospital of point-g. While there
was heterogeneity among the inclusion criteria of the
different protocols (Additional file 1: Table S1), with
some protocols excluding retreatment TB patients, we
do not expect this to have affected the prevalence of
resistance stratified within the new vs retreatment pa-
tient categories. However, the population referred to
this clinic and its collaborating SEREFO BSL-3 la-
boratory is likely enriched for retreatment patients
who had received multiple TB treatment episodes and
thus likely overestimates the overall prevalence of
DR-TB in Mali (Additional file 1: Table S1). Among
the 38 (50.7%) of MDR-TB patients whose isolate was
tested for second line drugs, we identified additional
resistance in seven (18.4%), which was stable over
time.
The present study was limited to Bamako city, the cap-
ital and largest city in Mali, where more than one third of
the country’s TB patients are diagnosed [5]. A larger sam-
ple size and representative sampling from all of the differ-
ent regions of Mali is therefore essential to obtain a true
country profile of TB drug resistance. The planning and
conduct of a true nationwide survey is however compli-
cated by current terrorism activities and resulting instabil-
ity in the north of the country. Despite its limitations, our
study showed that the number of MDR-TB patients
remained stable during the study period, (Table 1, Fig. 2),
as the largest variation in the activity of study protocols af-
fected recruitment of new TB patients, who had a low
MDR-TB prevalence. Consequently, for 2009 and 2010,
when few studies were recruiting, most patients screened
originated from the programmatic surveillance of retreat-
ment patients who were more likely to be drug resistant
patients (Fig. 2). If the prevalence of MDR-TB of 3.4%
among new patients, and 66.7% in previously treated pa-
tients were reflective of levels in the general population,
Mali could be classified as having high levels of TB drug
resistance, higher than many other West African countries
such as Benin and Senegal where the MDR-TB prevalence
was respectively 1.6 and 2.1% among newly diagnosed pa-
tients in 2007 [2, 3, 8]. In contrast, our data is similar to
those from Rwanda in 2007 (3.0% MDR among new pa-
tients), and to the WHO global estimates of 3.6% of
MDR-TB among new patients [1, 3], although MDR-TB
among previously treated patients worldwide was lower at
20% [1]. We found that approximately 7% of newly in-
fected patients had resistance to at least one drug. This is
relatively high as the rate of primary drug resistance can
be used to determine the efficacy of long-term tubercu-
losis treatment in the community [9]. As observed in
many other studies, we found that MDR-TB is more com-
mon in previously treated patients, which group is likely
enriched for patients failing multiple episodes of treatment
(Fig. 2). This high rate has implications for infection con-
trol, as recent mathematical models confirm that most ri-
fampicin resistant TB arises due to transmission of a
rifampicin resistant isolate rather than acquired drug re-
sistance [10]. Stratified analysis of patients with rifampicin
resistance vs. without rifampicin resistance found that pa-
tients with rifampicin resistance were more likely paucy
bacillary compared to the group without rifampicin resist-
ance (Table 3). We did not find a relation between MDR-
TB and HIV infection. The HIV seroprevalence we identi-
fied among TB patients in our studies (12.7%) was more
Table 2 Patterns of resistance to first-line anti-tuberculosis
drugs
Type of resistance New patients
(n = 236)
n (%)
Previously treated patients
(n = 101)
n (%)
Susceptible to all drugs 193 (81.8) 17 (16.8)
Any resistance
S 25 (10.6) 68 (67.3)
I 25 (10.6) 76 (75.2)
R 10 (4.2) 69 (68.3)
E 7 (3.0) 52 (51.5)
Monoresistance
S 13 (5.6) 3 (3.0)
I 10 (4.2) 2 (2.0)
R 1 (0.4) 1 (1.0)
E 0 (0) 1 (1.0)
Total 24 (10.2) 7 (6.9)
I + R resistant (MDR-TB)
SIR 0 (0) 5 (5.0)
IR 3 (1.3) 7 (6.9)
IRE 1 (0.4) 4 (4.0)
SIRE 4 (1.7) 51 (50.5)
Total 8 (3.4) 67 (66.3)
Other resistancea
SI 8 (3.4) 8 (7.9)
SIE 1(0.4) 2 (2.0)
SR 0 (0) 1 (1.0)
SRE 1 (0.4) 0 (0)
Total 10 (4.2) 11 (10.9)
S streptomycin, I isoniazid, R rifampicin, E ethambutol, MDR multidrug-
resistant, TB tuberculosis
aDefined as resistance to more than one drug, except for multidrug resistance
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than 11 times greater than in the general population
(1.1%)[11, 12], reinforcing the need for screening all TB
patients for HIV.
The outcome of MDR-TB treatment was poor for
those patients with results available, showing a high
mortality and a high loss to follow up. This may be
due to the poor efficacy and tolerability of the WHO
recommended treatment of MDR-TB. Fortunately, im-
plementation of an improved regimen of 9 months
duration has now been approved by the national eth-
ics committee [13].
We found no XDR-TB in our study population
although 18.4% of the MDR isolates had resistance to
either fluoroquinolone or second line injectable drugs,
and thus, the efficacy of second line treatment of these
strains may be impaired, due to resistance to either
fluoroquinolones or injectable drugs. All the MDR iso-
lates with resistance to either fluoroquinolone or
second-line injectable drugs were from previously
treated patients and none was identified among MDR
isolates from newly infected patients (Table 4). Among
the second line drugs, the prevalence of resistance to
Fig. 2 The evolution of Tuberculosis drug resistance within the 9-year period. a The evolution of MDR-TB patients from newly infected patients,
and (b) The evolution of MDR-TB from retreatment patients. The total number in each case includes the MDR cases. MDR-TB: multidrug resistant
Tuberculosis; DST, drug susceptibility testing. While the absolute number of MDR patients remains relatively stable, the proportion varies widely
because recruitment rates of new patients were variable. In 2006 and 2009, no MDR-TB patient was identified within recruited patients, and in
2010, no new TB patients were recruited and all retreatment patients tested were MDR
Table 3 Demographic characteristics and treatment antecedent
of patients with- and without rifampicin resistance
Characteristics Patients with
rifampicin resistance
(N = 79)
n (%)
Patients without
rifampicin resistance
(N = 258)
n (%)
P value
Age (year) 0–
14
0 (0) 2 (0.7) ———
15–24 14 (17.7) 62 (24) 0.24
25–34 26 (32.9) 92 (35.6) 0.65
35–44 19 (24) 41 (15.9) 0.09
45–54 9 (11.4) 33 (12.8) 0.74
≥ 55 7 (8.9) 22 (8.5) 0.92
Female 16 (20.2) 63 (24.4) 0.44
HIV+ 6 (7.6) 36 (13.9) 0.13
Previously
Treated
69 (87.3) 32 (12.4) <0.01
AFB Negative 8 (10.1) 6 (2.3) <0.01
1+ or 2+ 15 (18.9) 21 (8.1) <0.01
3+ 55 (69.6) 222 (86) <0.01
AFB acid fast bacilli, 1+ smear AFB positive at 1+, 2+ smear AFB positive at 2+,
3+ smear AFB positive at 3+
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capreomycin was the highest, which may impair
effective MDR TB therapy, and thus result in poor
outcome. The mono-resistance to kanamycin or
capreomycin seen in our study is uncommon, as there
usually is cross resistance to both drugs. Either this
constitutes a clonal infection, to be confirmed by
genotyping, or false resistance to capreomycin should
be taken into consideration.
Early detection of rifampicin resistant TB is clearly a
high priority for Mali, by increasing the coverage of
surveillance among retreatment patients, supported by
the use of the Xpert MTB/RIF at the NRL. Priorities for
the management of drug resistant TB patients in Mali
include the implementation of molecular and/or
phenotypic second line DST, including minimal inhibit-
ing concentrations (MICs) for ofloxacin or a different
fluoroquinolone, to identify those patients who would
benefit from high dose fluoroquinolone therapy. The
advent of a shorter and more effective MDR regimen
gives hope to improve on the dismal outcome of pa-
tients who were diagnosed with MDR in the past. This
should be accompanied by improved methods to follow
treatment efficacy in MDR patients, as monthly cul-
tures are often not available and associated with long
delays and high rates of contamination.
Conclusion
The drug resistance levels, including the number of
MDR-TB patients, found in this study population in
Mali over the past 9 years are relatively high, likely re-
lated to the selected referral population. While worri-
some, the numbers appeared stable over the study
period. As culture and DST are only available in
Bamako, the nationwide surveillance of retreatment
patients, as recommended by WHO, would benefit
from wider implementation of the GeneXpert MTB/
RIF assay. In the absence of a formal nationwide drug
resistance survey, such continuous surveillance will
provide more accurate results on nationwide drug re-
sistance rates. Second line drug resistance testing, cur-
rently not available in Mali, is another priority, to
allow MDR-TB patients to access appropriate treat-
ment regimens.
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